SCHEMBL17847655

SCHEMBL17847655

C[C@]1(O)CC[C@@H](NS(=O)(=O)c2ccc(Br)c(Cl)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45
ALOX15 P16050 1/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.43
HDAC8 Q9BY41 1/20 0.43
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42
PDK4 Q16654 1/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667871 1.00 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL29498511 1.00 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19667873 1.00 MAPK1 (0.46) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19995071 0.90 MAPK1 (0.48) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL29498633 0.90 MAPK1 (0.48) MAPK1SMN1; SMN2POLBTP53PKM
SCHEMBL19994813 0.86 ALDH1A1 (0.53) MAPK1SMN1; SMN2POLBLMNAALDH1A1
SCHEMBL17765473 0.85 KMT2A (0.55) MAPK1SMN1; SMN2POLBTP53LMNA
SCHEMBL17765475 0.85 KMT2A (0.55) MAPK1SMN1; SMN2POLBTP53LMNA
SCHEMBL16378516 0.85 KMT2A (0.55) MAPK1SMN1; SMN2POLBTP53LMNA
SCHEMBL21407132 0.82 KMT2A (0.49) MAPK1SMN1; SMN2POLBTP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262028-B1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(-4HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LTD (GB) 2021-10-27 EP disclosed
CN-107108508-B N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamide and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) -benzenesulfonamide compounds and their therapeutic use 皮姆科2664有限公司 2020-09-01 CN disclosed
US-20180297955-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2018-10-18 US disclosed
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use PIMCO 2664 LIMITED (GB) 2018-06-26 US disclosed
EP-3262028-A1 N-(4-HYDROXY-4-METHZL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(-4HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Pimco 2664 Limited (GB) 2018-01-03 EP disclosed
US-20170349551-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2017-12-07 US disclosed
WO-2016097001-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE PIMCO 2664 LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180297955-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE BRCA1, MYLK2, SOST MAPK1 2040/4885SMN1; SMN2 252/4885POLB 1934/4885
US-20170349551-A1 N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDE AND N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)-BENZENESULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE BRCA1, MYLK2, SOST MAPK1 2040/4885SMN1; SMN2 252/4885POLB 1934/4885
US-10005733-B2 N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use BRCA1, MYLK2, SOST MAPK1 2073/4885SMN1; SMN2 251/4885POLB 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.